BR0210976A - Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia - Google Patents

Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia

Info

Publication number
BR0210976A
BR0210976A BR0210976-0A BR0210976A BR0210976A BR 0210976 A BR0210976 A BR 0210976A BR 0210976 A BR0210976 A BR 0210976A BR 0210976 A BR0210976 A BR 0210976A
Authority
BR
Brazil
Prior art keywords
once daily
therapy
carvedilol
daily therapy
pharmaceutical composition
Prior art date
Application number
BR0210976-0A
Other languages
English (en)
Portuguese (pt)
Inventor
Dilip Shantilal Shanghvi
R Bala Ramesha Chary
Z Ziauddin Tyebji
Original Assignee
Sun Pharmaceutical Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sun Pharmaceutical Ind Ltd filed Critical Sun Pharmaceutical Ind Ltd
Publication of BR0210976A publication Critical patent/BR0210976A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0004—Osmotic delivery systems; Sustained release driven by osmosis, thermal energy or gas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Packaging Frangible Articles (AREA)
  • Indole Compounds (AREA)
BR0210976-0A 2001-05-17 2002-05-10 Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia BR0210976A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN464MU2001 IN191028B (enExample) 2001-05-17 2001-05-17
PCT/IN2002/000118 WO2002092078A1 (en) 2001-05-17 2002-05-10 Oral controlled release pharmaceutical composition for one-a-day therapy for the treatment and prophylaxis of cardiac and circulatory diseases

Publications (1)

Publication Number Publication Date
BR0210976A true BR0210976A (pt) 2004-10-05

Family

ID=11097247

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0210976-0A BR0210976A (pt) 2001-05-17 2002-05-10 Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia

Country Status (16)

Country Link
US (1) US20030035836A1 (enExample)
EP (1) EP1395258A1 (enExample)
JP (1) JP2004534031A (enExample)
KR (1) KR20040037026A (enExample)
CN (1) CN1525855A (enExample)
AU (1) AU2002314515B2 (enExample)
BE (1) BE1014328A7 (enExample)
BR (1) BR0210976A (enExample)
CA (1) CA2447005A1 (enExample)
HU (1) HUP0400607A3 (enExample)
IN (1) IN191028B (enExample)
MX (1) MXPA03010501A (enExample)
PL (1) PL370589A1 (enExample)
RU (1) RU2003133446A (enExample)
WO (1) WO2002092078A1 (enExample)
ZA (1) ZA200309724B (enExample)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4533531B2 (ja) 1998-04-03 2010-09-01 ビーエム リサーチ エイ／エス 制御放出組成物
WO2003024426A1 (en) * 2001-09-21 2003-03-27 Egalet A/S Controlled release solid dispersions
US20040234602A1 (en) 2001-09-21 2004-11-25 Gina Fischer Polymer release system
EP1429744A1 (en) 2001-09-21 2004-06-23 Egalet A/S Morphine polymer release system
US8101209B2 (en) * 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
EP1499310A4 (en) * 2002-04-30 2005-12-07 Sb Pharmco Inc MONOCITRATE MONOHYDRATE OF CARVEDILOL
MXPA04012923A (es) 2002-06-27 2005-03-31 Sb Pharmco Inc Sales de fosfato de carvedilol y/o solvatos de las mismas, composiciones correspondientes y/o metodos de tratamiento.
JP2005533822A (ja) 2002-06-27 2005-11-10 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド 臭化水素酸カルベジロール
EP1562552A1 (en) * 2002-11-08 2005-08-17 Egalet A/S Controlled release carvedilol compositions
US20060258652A1 (en) * 2002-11-22 2006-11-16 Haj-Yehia Abdullah I Beta-blockers having antioxidant and no-donor activity
ATE454886T1 (de) 2003-03-26 2010-01-15 Egalet As Matrixzubereitungen für die kontrollierte darreichung von arzneistoffen
WO2004084868A1 (en) 2003-03-26 2004-10-07 Egalet A/S Morphine controlled release system
US20070148229A1 (en) * 2003-04-24 2007-06-28 Jagotec Ag Tablet with coloured core
US7260685B2 (en) 2003-06-20 2007-08-21 Micron Technology, Inc. Memory hub and access method having internal prefetch buffers
PT3395338T (pt) * 2003-09-12 2019-07-23 Amgen Inc Formulação de dissolução rápida de cinacalcet hcl
US7120743B2 (en) 2003-10-20 2006-10-10 Micron Technology, Inc. Arbitration system and method for memory responses in a hub-based memory system
CA2547137A1 (en) * 2003-11-25 2005-06-09 Sb Pharmco Puerto Rico Inc. Carvedilol free base, salts, anhydrous forms or solvates thereof, corresponding pharmaceutical compositions, controlled release formulations, and treatment or delivery methods
JP2007512372A (ja) 2003-11-25 2007-05-17 エスビー・ファルムコ・プエルト・リコ・インコーポレイテッド カルベジロール塩、対応する組成物、送達および／または治療方法
EP1686967A4 (en) * 2003-11-25 2012-08-08 Smithkline Beecham Cork Ltd CARVEDILOL-FREE BASE, SALTS, WATER-FREE FORMS OR SOLVATES THEREOF, CORRESPONDING PHARMACEUTICAL COMPOSITIONS, CONTROLLED RELEASE FORMULAS AND TREATMENT OR DISPOSAL PROCEDURES
WO2005079752A2 (en) * 2004-02-11 2005-09-01 Rubicon Research Private Limited Controlled release pharmaceutical compositions with improved bioavailability
CA2611081C (en) * 2005-06-03 2016-05-31 Egalet A/S A drug delivery system for delivering active substances dispersed in a dispersion medium
US8367112B2 (en) * 2006-02-28 2013-02-05 Alkermes Pharma Ireland Limited Nanoparticulate carverdilol formulations
US8703804B2 (en) 2006-03-26 2014-04-22 Uti Limited Partnership Ryanodine receptor inhibitors and methods relating thereto
SI2049123T1 (sl) 2006-08-03 2013-04-30 Horizon Pharma Ag Zdravljenje revmatoznih bolezni z zadržanim sproščanjem glukokortikoida
US20080292695A1 (en) * 2006-12-01 2008-11-27 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
US20090028935A1 (en) * 2006-12-01 2009-01-29 Kristin Arnold Carvedilol forms, compositions, and methods of preparation thereof
NZ577560A (en) * 2007-01-16 2012-01-12 Egalet Ltd Use of i) a polyglycol and ii) an active drug substance for the preparation of a pharmaceutical composition for i) mitigating the risk of alcohol induced dose dumping and/or ii) reducing the risk of drug abuse
WO2008114276A1 (en) * 2007-03-16 2008-09-25 Lupin Limited Novel oral controlled release composition of carvedilol
BRPI0701904A2 (pt) * 2007-04-27 2008-12-09 Libbs Farmaceutica Ltda forma farmacÊutica de liberaÇço controlada de princÍpios ativos com solubilidade dependente do baixo ph do meio e processo para preparar a forma farmacÊutica
EP2155167A2 (en) 2007-06-04 2010-02-24 Egalet A/S Controlled release pharmaceutical compositions for prolonged effect
TWI494108B (zh) * 2009-01-26 2015-08-01 Nitec Pharma Ag 糖皮質激素用以製備嚴重夜間氣喘用之於延遲釋放型的藥物之用途
NZ594207A (en) 2009-02-06 2013-03-28 Egalet Ltd Immediate release composition resistant to abuse by intake of alcohol
NZ597283A (en) 2009-06-24 2013-07-26 Egalet Ltd Controlled release formulations
TWI415604B (zh) * 2009-09-29 2013-11-21 Tsh Biopharm Corp Ltd 調控釋放卡菲蒂羅劑型
JP5714562B2 (ja) * 2010-02-22 2015-05-07 第一三共株式会社 経口用徐放性固形製剤
ES2706880T3 (es) 2010-02-22 2019-04-01 Daiichi Sankyo Co Ltd Preparación sólida de liberación sostenida para uso oral
BR112015000150A2 (pt) 2012-07-06 2017-06-27 Egalet Ltd composições farmacêuticas dissuasoras de abuso de liberação controlada
CA2883077C (en) 2012-09-03 2017-03-07 Daiichi Sankyo Company, Limited Hydromorphone hydrochloride-containing oral sustained-release pharmaceutical composition
KR102241487B1 (ko) 2013-02-20 2021-04-16 주식회사 종근당 제어방출 펠릿으로 된 약제학적 조성물
KR102158339B1 (ko) 2016-02-05 2020-09-21 삼진제약주식회사 인습성이 개선된 카르베딜롤 속방성 제제

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2815926A1 (de) * 1978-04-13 1979-10-18 Boehringer Mannheim Gmbh Neue carbazolyl-(4)-oxy-propanolamin-derivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
US3916899A (en) * 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US5972389A (en) * 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
IL131713A (en) * 1997-03-11 2004-08-31 Arakis Ltd Dosage forms comprising separate portions of r- and s-enantiomers
IE970588A1 (en) * 1997-08-01 2000-08-23 Elan Corp Plc Controlled release pharmaceutical compositions containing tiagabine
US20020054911A1 (en) * 2000-05-11 2002-05-09 Boehringer Mannheim Pharmaceutical Corporation-Sm Ithkline Beckman Corporation, Limited Partnershi Novel oral dosage form for carvedilol
PE20001302A1 (es) * 1998-11-27 2000-11-30 Hoffmann La Roche Preparaciones de una combinacion farmaceutica que contiene carvedilol e hidroclorotiazida
US6515010B1 (en) * 1999-11-15 2003-02-04 Smithkline Beecham Corporation Carvedilol methanesulfonate
US6491949B2 (en) * 2000-01-14 2002-12-10 Osmotica Corp. Osmotic device within an osmotic device
US6352721B1 (en) * 2000-01-14 2002-03-05 Osmotica Corp. Combined diffusion/osmotic pumping drug delivery system
AU2001263813A1 (en) * 2000-04-03 2001-10-15 F.Hoffmann-La Roche Ag Concentrated solutions of carvedilol
WO2002065834A2 (en) * 2000-10-24 2002-08-29 Smithkline Beecham Corporation Novel formulations of carvedilol

Also Published As

Publication number Publication date
CA2447005A1 (en) 2002-11-21
KR20040037026A (ko) 2004-05-04
EP1395258A1 (en) 2004-03-10
US20030035836A1 (en) 2003-02-20
HUP0400607A2 (hu) 2004-07-28
BE1014328A7 (fr) 2003-08-05
ZA200309724B (en) 2005-05-25
MXPA03010501A (es) 2004-03-02
JP2004534031A (ja) 2004-11-11
PL370589A1 (en) 2005-05-30
CN1525855A (zh) 2004-09-01
RU2003133446A (ru) 2005-03-10
IN191028B (enExample) 2003-09-13
HUP0400607A3 (en) 2005-07-28
AU2002314515B2 (en) 2007-08-16
WO2002092078A1 (en) 2002-11-21

Similar Documents

Publication Publication Date Title
BR0210976A (pt) Composição farmacêutica de liberação oral controlada para a terapia de uma vez ao dia e método para a obtenção de um controle desejado sobre os nìveis plasmáticos de carvedilol em seres humanos para a terapia de uma vez ao dia
NO20022014D0 (no) Kontrollert frigjöring av hydrocodone formuleringer
WO2008079404A3 (en) Pharmaceutical compositions for treatment of parkinson's disease and related disorders
BR0311701A (pt) Formulação de dosagem multiparticulada com liberação controlada de lamotrigina, composição farmacêutica, processo para a preparação de uma composição farmacêutica de lamotrigina, método para a redução da flutuação no pico e no depósito da concentração da droga no plasma do sangue de um paciente, método para melhorar a complacência de um paciente pela redução da frequência de dosagem para uma vez por dia, método para a ministração mais segura de lamotrigina, método para proporcionar uma concentração terapêutica de plasma de sangue de lamotrigina e uso da formulação
BR9306841A (pt) Composição farmacêutica processo para proporcionar um tratamento anti-histamínico o qual não induz qualquer arritmia cardíaca significativa em um paciente ser humano e uso de uma composição para a mnaufactura de um medicamento para uso em um tratamento anti-histamínico
AR045289A1 (es) Forma de dosificacion oral de liberacion controlada que comprende 4-(2-di-n-propilaminoetil) - 2(3h)-indolona (ropi-nirol) y uso de dicha forma de dosificacion para la elaboracion de un medicamento
BR0214075A (pt) Dosagem unitária que compreende um análogo de prostaglandina para tratar constipação
Rizer et al. Macroglossia: etiologic considerations and management techniques
BR0016918A (pt) Processo e formulação para o tratamento de resistência a anti-hipertensivos e condições relacionadas
Yoshida Oral device therapy for the upper airway resistance syndrome patient
Kapetanakos et al. Rehabilitation of a patient after a total maxillectomy with a 2-piece magnetically retained obturator: A clinical report
BR112019026029A2 (pt) Formulações farmacêuticas orais de remogliflozina
Kumar et al. Management of postburn perioral contracture using a customized static commissural splint and intralesional injections of triamcinolone
BRPI0519016A2 (pt) agente preventivo ou terapÊutico para distérbios do sono, uso de uma droga, e, mÉtodo para prevenÇço e/ou tratamento de distérbios do sono
Deepika et al. Application of Polyvinyl chloride sheet as delayed surgical obturator in maxillectomy defects secondary to mucormycosis-A case series
US20030109495A1 (en) Nutraceutical solutions comprising dimethyl sulfoxide
BR9909786A (pt) Utilização de um glucocorticosteroide para a fabricação de um medicamento para tratar formas brandas/ precoces de copd (doença pulmonarobstrutiva crÈnica
BR0311180A (pt) Métodos para o tratamento de doenças e condições respiratórias utilizando um inibidor seletivo da inos
BR9916963A (pt) Bupropiona para tratamento de doenças virais
Pathak et al. Management of khalitya (hair fall) by ayurvedic formulations-a review
Hussain et al. The Evaluation of the Efficacy of Ketoprofen Analgesic Patches in Pain Control After Transalveolar Extraction of Impacted Third Molar
KR890015743A (ko) 근섬유아세포의 작용을 개선시키기 위한 tp-수용체 길항제의 용도
Turk et al. Comparison of acrylic/monolithic zirconia superstructures in all-on-4 concept
Wei et al. Esthetic outcomes of counterclockwise maxillomandibular advancement for middle aged Chinese severe obstructive sleep apnea patients
Doludeniz et al. Hemimasticatory Spasm: Treatment with Low-Level Laser Therapy

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 7A E 8A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2060 DE 29/06/2010.